Dendritic cell differentiation blocked by primary effusion lymphoma-released factors is partially restored by inhibition of P38 MAPK.

M. Cirone, L. Di Renzo, P. Trivedi, G. Lucania, G. Borgia, L. Frati, A. Faggioni

Research output: Contribution to journalArticle

Abstract

To better understand the molecular mechanisms underlying the dendritic cell (DC) defects in cancer, we analyzed which signaling pathway is implicated in the abnormal monocyte differentiation into DC determined by the presence of Primary effusion lymphoma (PEL) released factors. Our results indicate that the DC, obtained in this condition, together with phenotypic abnormalities and reduced allostimulatory function, showed hyperphosphorylation of signal transducer and activator of transcription 3 (STAT3) and p38 mitogen-activated protein kinase (MAPK) molecules, in comparison to the DC differentiated in the absence of PEL-released factors. The inhibition of p38 MAPK but not of STAT3 phosphorylation, with specific inhibitors, was able to revert the effect of the PEL-released factors on the DC phenotype. This study suggests that p38 MAPK signaling pathway is an important contributor to the abnormal differentiation of DC in PEL.

Original languageEnglish
Pages (from-to)1079-1086
Number of pages8
JournalInternational Journal of Immunopathology and Pharmacology
Volume23
Issue number4
Publication statusPublished - Oct 2010

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Dendritic cell differentiation blocked by primary effusion lymphoma-released factors is partially restored by inhibition of P38 MAPK.'. Together they form a unique fingerprint.

  • Cite this